Elevai Labs Inc
For the period ended Dec 31, 2023. Filed Mar 29, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 29, 2024
ELAB$1.69+7.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
Consolidated Statements of Changes in Stockholders’ Equity
| Series seed 1 preferred stock · Series seed 2 preferred stock · Series A preferred stock · Common Stock · Additional · Accumulated other | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of shares | Amount | Number of shares | Amount | Number of shares | Amount | Number of shares | Amount | paid-in capital | Accumulated deficit | comprehensive income | Total | |
| # | $ | # | $ | # | $ | # | $ | $ | $ | $ | $ | |
| Balance, January 1, 2022 | 213,730 | 21 | 3,635,252 | 364 | - | - | 9,526,808 | 952 | 1,371,194 | (922,105) | 202 | 450,628 |
| Private placements | - | - | - | - | 1,629,971 | 163 | - | - | 2,186,258 | - | - | 2,186,421 |
| Share issuance cost | - | - | - | - | - | - | - | - | (33,132) | - | - | (33,132) |
| Conversion of promissory notes | - | - | - | - | 231,828 | 23 | - | - | 130,860 | - | - | 130,883 |
| Share-based compensation | - | - | - | - | - | - | - | - | 171,869 | - | - | 171,869 |
| Exercise of stock options | - | - | - | - | - | - | 41,667 | 5 | 24,995 | - | - | 25,000 |
| Net loss for the year | - | - | - | - | - | - | - | - | - | (1,800,268) | - | (1,800,268) |
| Currency translation adjustment | - | - | - | - | - | - | - | - | - | - | (91) | (91) |
| Balance, December 31, 2022 | 213,730 | 21 | 3,635,252 | 364 | 1,861,799 | 186 | 9,568,475 | 957 | 3,852,044 | (2,722,373) | 111 | 1,131,310 |
| Balance, January 1, 2023 | 213,730 | 21 | 3,635,252 | 364 | 1,861,799 | 186 | 9,568,475 | 957 | 3,852,044 | (2,722,373) | 111 | 1,131,310 |
| Private placement | - | - | - | - | - | - | 487,859 | 49 | 1,463,537 | - | - | 1,463,586 |
| Exercise of stock options | - | - | - | - | - | - | 62,500 | 6 | 37,494 | - | - | 37,500 |
| Conversion of preferred shares on IPO | (213,730) | (21) | (3,635,252) | (364) | (1,861,799) | (186) | 5,710,781 | 571 | - | - | - | - |
| Shares issued alongside IPO | - | - | - | - | - | - | 1,500,000 | 150 | 5,999,850 | - | - | 6,000,000 |
| Share issuance costs for IPO | - | - | - | - | - | - | - | - | (991,632) | - | - | (991,632) |
| Share-based compensation | - | - | - | - | - | - | - | - | 487,738 | - | - | 487,738 |
| Net loss for the year | - | - | - | - | - | - | - | - | - | (4,301,517) | - | (4,301,517) |
| Currency translation adjustment | - | - | - | - | - | - | - | - | - | - | 91 | 91 |
| Balance, December 31, 2023 | - | - | - | - | - | - | 17,329,615 | 1,733 | 10,849,031 | (7,023,890) | 202 | 3,827,076 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.